SCHEMBL7091440

SCHEMBL7091440

O=C(Cc1ccc(F)cc1)Nc1ccc(C(=O)C[N+](=O)[O-])c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.53
MAPT P10636 4/20 0.48
THRB P10828 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 3/20 0.47
RECQL P46063 1/20 0.47
ALDH1A1 P00352 6/20 0.47
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 1/20 0.44
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7088364 0.91 MEN1 (0.58) GAAMAPTTHRBSMN1; SMN2LMNA
SCHEMBL7090480 0.89 MEN1 (0.56) GAAMAPTSMN1; SMN2LMNARECQL
SCHEMBL7085099 0.89 KMT2A (0.62) GAAMAPTTHRBSMN1; SMN2LMNA
SCHEMBL7088706 0.88 MEN1 (0.60) GAAMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL7088628 0.88 MEN1 (0.52) GAAMAPTTHRBLMNARECQL
SCHEMBL7088341 0.87 MEN1 (0.52) MAPTSMN1; SMN2LMNAALDH1A1MEN1
SCHEMBL7088352 0.86 SMN1; SMN2 (0.52) MAPTSMN1; SMN2LMNAALDH1A1MEN1
SCHEMBL7088259 0.84 ALDH1A1 (0.59) MAPTSMN1; SMN2LMNARECQLALDH1A1
SCHEMBL7088770 0.83 MEN1 (0.55) GAAMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL7085782 0.81 MEN1 (0.47) GAAMAPTSMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
CN-1257474-A New nitromethylketone compounds, process for their preparation and compositions containing them MERCK PATENT GMBH (DE) 2000-06-21 CN disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
US-5932765-A REDUCTASE INHIBITORS MERCK PATENT GESELLSCHAFT MIT (DE) 1999-08-03 US disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 GAA 231/4885MAPT 3746/4885THRB 1759/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 GAA 998/4885MAPT 2260/4885THRB 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.